Outcomes of tocilizumab and sarilumab for hospitalized patients with COVID-19: retrospective study
Abstract Introduction Tocilizumab (TZ) and sarilumab (SL), IL-6 receptor antagonists, were utilized during the pandemic, yet direct comparisons remain limited, particularly in resource-constrained settings facing drug shortages. Hypothesis This study aimed to evaluate whether TZ and SL yield compara...
Saved in:
| Main Authors: | Ashraf Mokhtar Madkour, Ashraf Abbas El Maraghy, Boles Raafat Fadly, Ragy Mamdouh Ghaly |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | The Egyptian Journal of Bronchology |
| Online Access: | https://doi.org/10.1186/s43168-025-00423-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01) -
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.
by: Peter J Godolphin, et al.
Published: (2022-01-01) -
Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
by: Rajan Chamlagain, et al.
Published: (2021-01-01) -
Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients
by: Ishtiaq Ahmad, et al.
Published: (2024-06-01) -
Revitalizing conventional TBNA in a resource-constrained academic center: Ain Shams University Hospital’s experience with non-visible extraluminal pathologies
by: Somaya Ahmed Mohamed Alsaead, et al.
Published: (2025-06-01)